Delivery of Neuropeptides from the Periphery to the Brain: Studies with Enkephalin
- 16 February 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 1 (5) , 399-406
Abstract
Many peptides with the potential of therapeutic action for brain disorders are not in clinical use because they are unable to cross the blood−brain barrier (BBB) following peripheral administration. We have developed two potential strategies for the delivery of peptides to the brain and demonstrated their feasibility with enkephalins. In the first approach, designated induced reversible lipophilization, Leu/Met Enkephalins were converted to 9-fluorenylmethoxycarbonyl (Fmoc) derived lipophilic prodrug analogues, which undergo slow, spontaneous hydrolysis under physiological conditions, generating the native agonists. In contrast to Enkephalin, Fmoc-Met-Enkephalin was found to facilitate an analgesic effect following intraperitoneal administration in mice. Fmoc-Leu-Enkephalin was not analgesic. In the second approach, Enkephalin was linked to BBB transport vectors through an Fmoc based linker spacer, forming conjugates that slowly release Enkephalin under physiological conditions. A pronounced antinociceptive response was thus obtained following intraperitoneal administration of either cationized-human serum albumin-Fmoc-Enkephalin or polyethylene glycol5-Fmoc-Enkephalin. Derivatives of Enkephalin covalently linked to the same BBB-transport vectors through a stable (nonreversible) chemical bond were not analgesic. In summary, we have demonstrated that lipophilicity can be conferred to hydrophilic peptides to a degree permitting the permeation of the BBB by passive diffusion, without the drawback of agonist inactivation, which is often caused by irreversible derivatization. Similarly, in the second strategy, the conjugation to BBB-permeable vectors overcomes the obstacle of peptide inactivation by releasing the active form in the central nervous system.Keywords
This publication has 21 references indexed in Scilit:
- New Technologies to Prolong Life-time of Peptide and Protein Drugs In vivoInternational Journal of Peptide Research and Therapeutics, 2006
- Albumin−Insulin Conjugate Releasing Insulin Slowly under Physiological Conditions: A New Concept for Long-Acting InsulinBioconjugate Chemistry, 2005
- Reversible PEGylation of peptide YY3‐36 prolongs its inhibition of food intake in miceFEBS Letters, 2005
- The blood-brain barrier: Bottleneck in brain drug developmentNeuroRX, 2005
- Prolonging the Action of Protein and Peptide Drugs by a Novel Approach of Reversible Polyethylene Glycol ModificationJournal of Biological Chemistry, 2004
- Effects of intracerebroventricularly administered chimeric peptide of metenkephalin and FMRFa—[D-Ala2]YFa—on antinociception and its modulation in miceBrain Research Bulletin, 2001
- Prolonging the half-life of human interferon-α2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-α2Proceedings of the National Academy of Sciences, 2001
- A new approach for prolonging the half-life of peptides, proteins and low-molecular-weight drugs in vivoDrugs of the Future, 2001
- Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier.Proceedings of the National Academy of Sciences, 1994
- The clinical efficacy of poly(ethylene glycol)-modified proteinsJournal of Controlled Release, 1990